Paediatric Oncology and Haematology

How we manage Retinoblastoma in 2016

Registration closed

Description

This meeting is of interest to ophthalmologists, pediatric oncologists, basic researchers, members of advocacy group and all other specialties in relationship with the care of children with retinoblastoma who wish to participate in vibrant discussions about the current controversies in the management of this tumor and obtain an updated overview from worldwide experts in the field.

The management of retinoblastoma changed dramatically in the past few years after the advent of new treatment modalities, such as intra-arterial and intravitreous chemotherapy as well as genomic data. This meeting is of interest to ophthalmologists, pediatric oncologists, basic researchers, members of advocacy group and all other specialties in relationship with the care of children with retinoblastoma who wish to participate in vibrant discussions about the current controversies in the management of this tumor and obtain an updated overview from worldwide experts in the field.

Directors

  • Guillermo L. Chantada MD, 
  • Dr. Jaume Català MD

Coordinator

  • Dr. Hector Salvador MD.

  

IN COLLABORATION WITH

Supporting organizations

  • Hospital Sant Joan de Déu.
  • Fund for Ophthalmic Knowkledge.
  • VCN Biosciences.

Scientific support

  • European Retinoblastoma Group

Aimed at

Medical specialists in ophthalmology, pediatric oncology, basic research, biology, geneticists, nurses, parental organizations and advocacy groups.

Objectives

To give an updated vision brings over of the managing of the retinoblastoma in 2016 in all his aspects.

  • To spread knowledge brings over of the controversies in the basic biology of the retinoblastoma.
  • To discuss the controversies in the evaluation of the patients with retinoblastoma so much from the point of view of the extension of his disease to ocular level and extraocular.
  • To discuss the points of agreement and controversy in the conservative and systemic treatment of the retinoblastoma.
  • To put in global perspective the new developments in the managing of the retinoblastoma.

Contents

TOPICS

  • Treatment of retinoblastoma in 2016. When to use systemic, intra-arterial and intravitreal chemotherapy?
  • Management of high risk and extraocular retinoblastoma. Who needs adjuvant therapy?
  • How to stage and follow patients with retinoblastoma?
  • Basic biology in retinoblastoma. From basic science to new molecular targets
  • Treatment of retinoblastoma in developing countries.

IN COLLABORATION WITH 

Key information

Paediatric Oncology and Haematology
Language Catalan